Curanex Pharmaceuticals Inc Common Stock

NASDAQ: CURX · Healthcare · Biotechnology

PublicHQ Jericho, NY · NassauCIK 0002025942Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 64DQ —GM —SS 22

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$4.2M

Employees

as of 2026-08-23

Market cap

$6.7M

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$4.2M-$4.2M2025

Operating income-$4.2M-$4.2M2025

Total assets$11.6M$11.6M2025

Liabilities$361.0k$361.0k2025

Equity$11.2M$11.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Curanex Pharmaceuticals Inc Common Stock’s financial profile?

Curanex Pharmaceuticals Inc Common Stock earned -$4.2M in FY2025 net income.

Peers · Healthcare

Apimeds Pharmaceuticals US, Inc——Liminatus Pharma, Inc. Class A Common Stock——Curative Biotechnology, Inc.——Imagion Biosystems Limited——Acurx Pharmaceuticals, Inc.——Cardiac Biotech Solutions Inc.——

Neighbors

Nassau →

Broadridge Financial Solutions, Inc.$6.9B77B+Kimco Realty Corporation$2.1B69B Flagstar Financial, Inc.$27.0M42D Veeco Instruments Inc.$664.3M71B Getty Realty Corp.$221.7M78B+Global Industrial Co$1.4B75B+

Key facts

CEOJun Liu

SectorHealthcare

IndustryBiotechnology

HeadquartersJericho, NY

ExchangeNASDAQ: CURX

Employees6

IPO date2025-08-26

Latest filings

8-K2026-08-17 10-Q2026-08-14 8-K2026-05-14 10-Q2026-05-14 8-K2026-05-07 8-K2026-04-02 10-K2026-03-30 8-K2026-03-06

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.